What are your research interests?
- Haematology ( study of blood disorders)
- Leukemia (blood cancers)
- Coagulation (clotting) and venous thromboembolism
Why did you get into research?
Blood cancers are devasting for the patient and their families. As a clinician researcher, the unique opportunity to work with patients and to translate the developments in the lab directly to clinical practice is a constant inspiration in the journey to treat blood diseases.
What would be the ultimate goal for your research?
Working with my clinical colleagues, students and other researchers, we aim to bring novel drugs and diagnostics as well as introduce health system changes, bring world class research in haematology to the Hunter to improve outcomes for patients with blood disorders.
Dr Enjeti obtained his postgraduate physician qualifications from the UK Royal College of Physicians and specialist haematology from the Royal College of Pathologists of Australasia (2006). His physician and specialist haematology training has spanned across India, UK, Singapore and Australia including specialist training in genetics and molecular genetics where he has contributed to a high impact publication outlining geographical variations in AML genetics. Other training includes a MD in Pathology (Pondicherry University 2001), GradCert in Bioethics (Monash, 2012) as well as Masters in Clinical Epidemiology (Molecular Genetics, University of Newcastle 2010).
Dr Enjeti is currently employed as a clinical haematologist at the Calvary Mater Hospital, with a special interest in acute myeloid leukaemia (blood cancer) and myelodysplasia (precursor to blood cancer). He is an active member of the Hunter Cancer Research Alliance (HCRA) where he has established active collaborations with cancer researchers locally and across the state. He has over 35 peer-reviewed publications, numerous conference presentations and three book chapters.
Dr Enjeti is the recipient of the prestigious ‘visiting fellowship’ in Molecular Oncologic Pathology Strategic Health Research Training Program in Cancer Research, Canada (funded by the Terry Fox Foundation) for the year 2016. Dr Enjeti was the recipient of the HCRA fellowship in 2015 and more recently was awarded aTranslational Research Fellowship from Pathology NSW - Hunter/HNE LHD /HCRA and Calvary Mater Hospital (2017-19) to pursue translational clinical research in Haematology. His research focus includes early phase clinical trials in haematological malignancies( AML/MDS) and translational diagnostics as well as in circulating microvesicles and their impact on thrombosis/cancer/abnormal clonal haemopoiesis (his PhD work).
Dr Enjeit manages several current acute leukemia, myeloma and myelodysplasia clinical trials (has been an investigator in > 25 past clinical trials) at the Calvary Mater Hospital. He is an active member of ALLG (Australasian Leukemia and Lymphoma Group) subcommittees - leukemia disease group and the basic science subcommittees. He is currently a principal investigator at his site for several ongoing national and international trials in Myeloma, lymphoma, leukemia and myelodysplasia. He has strong research interest in exploring novel oral therapies for haematological malignancies and an international phase I trial , in which he was a principal investigator led to FDA approval of a new therapy for blood cancer .He also is the molecular haematology lead for his hospital and has been instrumental in setting up array as well as next generation sequencing for molecular targeting / prognostication in Myeloma, lymphoid and other myeloid malignancies at Pathology North/ Pathology NSW.
I am working together with several others sharing my passion for solving challenges in blood cancer. Our focus is to develop new drugs which are easily administered and have less toxicity than conventional chemotherapy. I am also involved with my colleagues in the Australasian Leukemia and Lymphoma group to develop approaches to clinical trials in blood cancers which will evaluate lateral approaches to therapy and bring drugs more rapidly to patients in Australia.
- Early phase clinical trials with focus on MDS and AML
- Translational diagnostics in Haemtatology
- Service transformation projects with focus on transfusion
- Understanding the biology of coagulation and risk reduction strategies for venous thromboembolism
ABC Newcastle interview with Kia Handley - 2 July 2019